Long-term risk of cardiovascular disease in Hodgkin lymphoma survivors-Retrospective cohort analyses and a concept for prospective intervention

被引:25
作者
Andersson, Anne [1 ]
Naslund, Ulf [2 ]
Tavelin, Bjorn [3 ]
Enblad, Gunilla [4 ]
Gustavsson, Anita [5 ]
Malmer, Beatrice [1 ]
机构
[1] Umea Univ, Dept Radiat Sci, S-90185 Umea, Sweden
[2] Umea Univ Hosp, Dept Cardiol, Ctr Heart, S-90185 Umea, Sweden
[3] Umea Univ, Ctr Oncol, S-90185 Umea, Sweden
[4] Uppsala Univ, Sect Oncol, Dept Oncol Radiol & Clin Immunol, Uppsala, Sweden
[5] Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden
关键词
Hodgkin; survivorship; cardiovascular disease; prevention; CORONARY-ARTERY-DISEASE; MEDIASTINAL IRRADIATION; RADIATION; THERAPY; MORTALITY;
D O I
10.1002/ijc.24147
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous studies have shown increased cardiovascular mortality as late side effects in Hodgkin lymphoma (HL) patients. This study identifies stratifying risk factors for surveillance and defines concepts for a clinical feasible and noninvasive prospective protocol for intervention of cardiovascular side effects. HL patients diagnosed between 1965 and 1995 (n = 6.946) and their first-degree relatives (FDR) were identified through the Swedish Cancer Registry and the Swedish Multigeneration Registry. For the HL and FDR cohort, in-patient care for cardiovascular disease (CVD) was registered through the Hospital Discharge Registry, Sweden. Standard incidence ratios of developing CVD for the HL cohort were calculated. A markedly increased risk for in-patient care of CVD was observed in HL patients with HL diagnosed at age 40 years or younger and with more than 10 years follow-up. In the HL survivors, a family history of congestive heart failure (CHF) and coronary artery disease (CAD) increased the risk for these diseases. The Swedish Hodgkin Intervention and Prevention study started in 2007. In the pilot feasibility study for prospective intervention (47 patients), about 25% of the cases had side effects and laboratory abnormalities. These patients were referred to a cardiologist or general practitioner. In the prospective cohort, a positive family history for CHF or CAD could be a stratifying risk factor when setting up a surveillance model. The prospective on-going study presents an intervention model that screens and treats for comorbidity factors. This article also presents an overview of the study concept. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:1914 / 1917
页数:4
相关论文
共 25 条
[1]   Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy [J].
Adams, MJ ;
Lipsitz, SR ;
Colan, SD ;
Tarbell, NJ ;
Treves, ST ;
Diller, L ;
Greenbaum, N ;
Mauch, P ;
Lipshultz, SE .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) :3139-3148
[2]   Late cardiotoxicity after treatment for Hodgkin lymphoma [J].
Aleman, Berthe M. P. ;
van den Belt-Dusebout, Alexandra W. ;
De Bruin, Marie L. ;
van 't Veer, Mars B. ;
Baaijens, Margreet H. A. ;
de Boers, Jan Paul ;
Hart, Augustinus A. M. ;
Klokman, Willem J. ;
Kuenen, Marianne A. ;
Ouwens, Gabey M. ;
Bartelink, Harry ;
van Leeuwen, Flora E. .
BLOOD, 2007, 109 (05) :1878-1886
[3]   Long-term cause-specific mortality of patients treated for Hodgkin's disease [J].
Aleman, BMP ;
van den Belt-Dusebout, AW ;
Klokman, WJ ;
van't Veer, MB ;
Bartelink, H ;
van Leeuwen, FE .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) :3431-3439
[4]   Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications [J].
Basavaraju, SR ;
Easterly, CE .
MEDICAL PHYSICS, 2002, 29 (10) :2391-2403
[5]  
Breslow N E, 1980, IARC Sci Publ, P5
[6]   American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects [J].
Carver, Joseph R. ;
Shapiro, Charles L. ;
Ng, Andrea ;
Jacobs, Linda ;
Schwartz, Cindy ;
Virgo, Katherine S. ;
Hagerty, Karen L. ;
Somerfield, Mark R. ;
Vaughn, David J. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) :3991-4008
[7]   Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease [J].
Constine, LS ;
Schwartz, RG ;
Savage, DE ;
King, V ;
Muhs, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 39 (04) :897-906
[8]   EPIDEMIOLOGY OF SILENT-MYOCARDIAL-ISCHEMIA IN ASYMPTOMATIC MIDDLE-AGED MEN (THE ECCIS PROJECT) [J].
FAZZINI, PF ;
PRATI, PL ;
ROVELLI, F ;
ANTONIUCCI, D ;
MENGHINI, F ;
SECCARECCIA, F ;
MENOTTI, A .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (18) :1383-1388
[9]   Cardiac risk after mediastinal irradiation for Hodgkin's disease [J].
Glanzmann, C ;
Kaufmann, P ;
Jenni, R ;
Hess, OM ;
Huguenin, P .
RADIOTHERAPY AND ONCOLOGY, 1998, 46 (01) :51-62
[10]   A systematic overview of radiation therapy effects in Hodgkin's lymphoma [J].
Gustavsson, A ;
Osterman, B ;
Cavallin-Ståhl, E .
ACTA ONCOLOGICA, 2003, 42 (5-6) :589-604